Hikma Pharmaceuticals Plc (HIK):企業の財務・戦略的SWOT分析

◆英語タイトル:Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH57970FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Hikma Pharmaceuticals Plc (HIK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East and North Africa (MENA) and Europe and rest of the world. Hikma Pharmaceuticals is headquartered in London, the UK.

Hikma Pharmaceuticals Plc Key Recent Developments

Feb 25,2021: Hikma delivers strong performance in 2020
Feb 18,2021: Hikma donates over $4 million USD in medicines and signs new long-term partnerships with Dispensary of Hope, Direct Relief, Americares, Brother’s Brother Foundation and the National Children’s Cancer Society
Nov 30,2020: Amarin files patent infringement lawsuit against Hikma
Nov 05,2020: Hikma Pharmaceuticals – Board and committee changes
Nov 05,2020: Hikma continues strong 2020 performance and updates full year guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Hikma Pharmaceuticals Plc – Key Facts
Hikma Pharmaceuticals Plc – Key Employees
Hikma Pharmaceuticals Plc – Key Employee Biographies
Hikma Pharmaceuticals Plc – Major Products and Services
Hikma Pharmaceuticals Plc – History
Hikma Pharmaceuticals Plc – Company Statement
Hikma Pharmaceuticals Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Hikma Pharmaceuticals Plc – Business Description
Business Segment: Branded
Overview
Performance
Business Segment: Generics
Overview
Performance
Business Segment: Injectables
Overview
Performance
Business Segment: Others
Performance
Geographical Segment: Europe and Rest of the World
Performance
Geographical Segment: MENA
Performance
Geographical Segment: United Kingdom
Performance
Geographical Segment: United States
Performance
Hikma Pharmaceuticals Plc – Corporate Strategy
Hikma Pharmaceuticals Plc – SWOT Analysis
SWOT Analysis – Overview
Hikma Pharmaceuticals Plc – Strengths
Hikma Pharmaceuticals Plc – Weaknesses
Hikma Pharmaceuticals Plc – Opportunities
Hikma Pharmaceuticals Plc – Threats
Hikma Pharmaceuticals Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 25, 2021: Hikma delivers strong performance in 2020
Feb 18, 2021: Hikma donates over $4 million USD in medicines and signs new long-term partnerships with Dispensary of Hope, Direct Relief, Americares, Brother’s Brother Foundation and the National Children’s Cancer Society
Nov 30, 2020: Amarin files patent infringement lawsuit against Hikma
Nov 05, 2020: Hikma Pharmaceuticals – Board and committee changes
Nov 05, 2020: Hikma continues strong 2020 performance and updates full year guidance
Oct 20, 2020: Hikma and Arecor expand collaboration
Aug 18, 2020: DoseID launches to expand RFID interoperability and performance in healthcare
Aug 07, 2020: Hikma Pharmaceuticals : Half-year Report
Aug 07, 2020: Hikma delivers strong first half performance and raises full year guidance
Jun 25, 2020: Jochen Gann resigns from the Board of Hikma
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Hikma Pharmaceuticals Plc, Key Facts
Hikma Pharmaceuticals Plc, Key Employees
Hikma Pharmaceuticals Plc, Key Employee Biographies
Hikma Pharmaceuticals Plc, Major Products and Services
Hikma Pharmaceuticals Plc, History
Hikma Pharmaceuticals Plc, Subsidiaries
Hikma Pharmaceuticals Plc, Joint Venture
Hikma Pharmaceuticals Plc, Key Competitors
Hikma Pharmaceuticals Plc, Ratios based on current share price
Hikma Pharmaceuticals Plc, Annual Ratios
Hikma Pharmaceuticals Plc, Annual Ratios (Cont...1)
Hikma Pharmaceuticals Plc, Annual Ratios (Cont...2)
Hikma Pharmaceuticals Plc, Interim Ratios
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Hikma Pharmaceuticals Plc (HIK):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Orcas Power & Light Cooperative:企業の戦略的SWOT分析
    Orcas Power & Light Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Grupo Posadas Sab De Cv:企業の戦略・SWOT・財務分析
    Grupo Posadas Sab De Cv - Strategy, SWOT and Corporate Finance Report Summary Grupo Posadas Sab De Cv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Kaiser Permanente:企業の戦略・SWOT・財務分析
    Kaiser Permanente - Strategy, SWOT and Corporate Finance Report Summary Kaiser Permanente - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Sixt SE:企業の戦略・SWOT・財務情報
    Sixt SE - Strategy, SWOT and Corporate Finance Report Summary Sixt SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Go-Ahead Group Plc:企業の戦略・SWOT・財務分析
    Go-Ahead Group Plc - Strategy, SWOT and Corporate Finance Report Summary Go-Ahead Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • The Swatch Group Ltd:企業の戦略・SWOT・財務情報
    The Swatch Group Ltd - Strategy, SWOT and Corporate Finance Report Summary The Swatch Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Bonterra Energy Corp (BNE)-石油・ガス分野:企業M&A・提携分析
    Summary Bonterra Energy Corp. (Bonterra) is an oil and gas company. It acquires and develops producing or undeveloped oil and gas properties. It produces crude oil, natural gas and natural gas liquids. The company principally operates in the provinces of Alberta, British Columbia and Saskatchewan in …
  • Jupiter Energy Ltd (JPR):石油・ガス:M&Aディール及び事業提携情報
    Summary Jupiter Energy Ltd (Jupiter Energy) is an oil exploration and production company that carries out acquisition, exploration, production, and develops oil and natural gas properties. The company holds an exploration permit in the oil-rich Mangistau Basin in West Kazakhstan. It also holds inter …
  • GWA Group Ltd (GWA):企業の財務・戦略的SWOT分析
    GWA Group Ltd (GWA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Mitsui Chemicals, Inc.:企業の戦略・SWOT・財務分析
    Mitsui Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mitsui Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • GlaxoSmithKline Plc (GSK):企業の財務・戦略的SWOT分析
    GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Briggs & Stratton Corporation:企業の戦略・SWOT・財務分析
    Briggs & Stratton Corporation - Strategy, SWOT and Corporate Finance Report Summary Briggs & Stratton Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Copenhagen Airports AS:企業の戦略・SWOT・財務情報
    Copenhagen Airports AS - Strategy, SWOT and Corporate Finance Report Summary Copenhagen Airports AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • InFlectis BioScience-製薬・医療分野:企業M&A・提携分析
    Summary InFlectis BioScience (InFlectis) is a drug discovery company that discovers and develops small molecule drugs that target the unfolded protein response (UPR) to treat misfolding protein disorders such as age-related and neurodegenerative diseases. The company’s product lead candidate IFB-088 …
  • Turisthotel d.d.:企業の戦略・SWOT・財務情報
    Turisthotel d.d. - Strategy, SWOT and Corporate Finance Report Summary Turisthotel d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • The Hershey Co:戦略・SWOT・企業財務分析
    The Hershey Co - Strategy, SWOT and Corporate Finance Report Summary The Hershey Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • St. Jude Medical, Inc.:企業のM&A・事業提携・投資動向
    St. Jude Medical, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's St. Jude Medical, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Domtar Corporation:戦略・SWOT・企業財務分析
    Domtar Corporation - Strategy, SWOT and Corporate Finance Report Summary Domtar Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Flex Pharma Inc (FLKS):製薬・医療:M&Aディール及び事業提携情報
    Summary Flex Pharma Inc (Flex Pharma) is a clinical-stage biotechnology company that offers discovery and development of innovative and proprietary treatments for muscle cramps, spasms and spasticity connected to the severe neurological diseases of ALS, MS, fibromyalgia, hypomagnesemia, hypocalcemia …
  • CytoSorbents Corp (CTSO):企業の財務・戦略的SWOT分析
    Summary CytoSorbents Corp (CytoSorbents), formerly MedaSorb Technologies Corp, is a critical care immunotherapy company that develops blood purification products. Its flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme systemic inflammation in seriou …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆